{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:47:39Z","timestamp":1784875659739,"version":"3.55.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41585-021-00504-x","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T13:07:16Z","timestamp":1629810436000},"page":"686-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["The cognitive effect of anticholinergics for patients with overactive bladder"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-558X","authenticated-orcid":false,"given":"Blayne","family":"Welk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-3259","authenticated-orcid":false,"given":"Jalesh N.","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"504_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","volume":"65","author":"I Milsom","year":"2014","unstructured":"Milsom, I. et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur. Urol. 65, 79\u201395 (2014).","journal-title":"Eur. Urol."},{"key":"504_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167\u2013178 (2002).","journal-title":"Neurourol. Urodyn."},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.eururo.2007.08.007","volume":"52","author":"S Heidler","year":"2007","unstructured":"Heidler, S. et al. The natural history of lower urinary tract symptoms in females: analysis of a health screening project. Eur. Urol. 52, 1744\u20131750 (2007).","journal-title":"Eur. Urol."},{"key":"504_CR4","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet, B. et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur. Urol. 75, 988\u20131000 (2019). An excellent article on OAB pathophysiology that includes a review of several potential mechanisms and phenotypes of OAB.","journal-title":"Eur. Urol."},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley, E. A., Lightner, D. J., Faraday, M. & Vasavada, S. P. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU guideline amendment. J. Urol. 193, 1572\u20131580 (2015).","journal-title":"J. Urol."},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","volume":"73","author":"AK Nambiar","year":"2018","unstructured":"Nambiar, A. K. et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur. Urol. 73, 596\u2013609 (2018).","journal-title":"Eur. Urol."},{"key":"504_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/08998280.2007.11928310","volume":"20","author":"K Hesch","year":"2017","unstructured":"Hesch, K. Agents for treatment of overactive bladder: a therapeutic class review. Bayl. Univ. Med. Cent. Proc. 20, 307\u2013314 (2017).","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"504_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1517\/17425255.2012.714365","volume":"8","author":"ULR Maggiore","year":"2012","unstructured":"Maggiore, U. L. R. et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin. Drug Met. 8, 1387\u20131408 (2012).","journal-title":"Expert Opin. Drug Met."},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple, C. R. et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur. Urol. 54, 543\u2013562 (2008).","journal-title":"Eur. Urol."},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","volume":"65","author":"K Maman","year":"2014","unstructured":"Maman, K. et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur. Urol. 65, 755\u2013765 (2014).","journal-title":"Eur. Urol."},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco, A. G. et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N. Engl. J. Med. 367, 1803\u20131813 (2012).","journal-title":"N. Engl. J. Med."},{"key":"504_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell, G. et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 8, e021889 (2018).","journal-title":"BMJ Open"},{"key":"504_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016718","volume":"6","author":"TM Kessler","year":"2011","unstructured":"Kessler, T. M. et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS ONE 6, e16718 (2011).","journal-title":"PLoS ONE"},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland, C. A. C. et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern. Med. 179, 1084\u20131093 (2019).","journal-title":"JAMA Intern. Med."},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"k1315","DOI":"10.1136\/bmj.k1315","volume":"361","author":"K Richardson","year":"2018","unstructured":"Richardson, K. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 361, k1315 (2018). An often-quoted study that suggests a potential causal association between anticholinergics and the eventual diagnosis of dementia.","journal-title":"BMJ"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay, G. et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. 50, 317\u2013326 (2006). A prospective clinical study that demonstrated that short-term oxybutynin use is associated with 10 years of ageing of the brain.","journal-title":"Eur. Urol."},{"key":"504_CR17","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care. Lancet 390, 2673\u20132734 (2017).","journal-title":"Lancet"},{"key":"504_CR18","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1056\/NEJMcp0910237","volume":"364","author":"RC Petersen","year":"2011","unstructured":"Petersen, R. C. Clinical practice. Mild cognitive impairment. N. Engl. J. Med. 364, 2227\u20132234 (2011).","journal-title":"N. Engl. J. Med."},{"key":"504_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40266-017-0474-6","volume":"34","author":"VH Decalf","year":"2017","unstructured":"Decalf, V. H. et al. Older people\u2019s preferences for side effects associated with antimuscarinic treatments of overactive bladder: a discrete-choice experiment. Drug Aging 34, 615\u2013623 (2017).","journal-title":"Drug Aging"},{"key":"504_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/SPV.0000000000000423","volume":"23","author":"TN Thomas","year":"2017","unstructured":"Thomas, T. N. & Walters, M. D. AUGS consensus statement: association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med. Reconstr. Surg. 23, 177\u2013178 (2017).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"504_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","volume":"64","author":"A Wagg","year":"2013","unstructured":"Wagg, A., Dale, M., Tretter, R., Stow, B. & Compion, G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur. Urol. 64, 74\u201381 (2013).","journal-title":"Eur. Urol."},{"key":"504_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/01.ju.0000148963.21096.5d","volume":"173","author":"RB Lipton","year":"2005","unstructured":"Lipton, R. B., Kolodner, K. & Wesnes, K. Assessment of cognitive function of the elderly population. J. Urol. 173, 493\u2013498 (2005).","journal-title":"J. Urol."},{"key":"504_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1464-410X.2005.05745.x","volume":"96","author":"GG Kay","year":"2005","unstructured":"Kay, G. G. & Wesnes, K. A. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 96, 1055\u20131062 (2005).","journal-title":"BJU Int."},{"key":"504_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/14740330903260790","volume":"8","author":"KA Wesnes","year":"2009","unstructured":"Wesnes, K. A., Edgar, C., Tretter, R. N. & Bolodeoku, J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10\u2009mg. Expert Opin. Drug Saf. 8, 615\u2013626 (2009).","journal-title":"Expert Opin. Drug Saf."},{"key":"504_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2012.05.2543","volume":"124","author":"GG Kay","year":"2015","unstructured":"Kay, G. G. et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad. Med. 124, 7\u201315 (2015).","journal-title":"Postgrad. Med."},{"key":"504_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SPV.0000000000000374","volume":"23","author":"EJ Geller","year":"2017","unstructured":"Geller, E. J. et al. Effect of trospium chloride on cognitive function in women aged 50 and older. Female Pelvic Med. Reconstr. Surg. 23, 118\u2013123 (2017).","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"key":"504_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5213\/inj.1834996.498","volume":"22","author":"K Kosilov","year":"2018","unstructured":"Kosilov, K. et al. Influence of the short-term intake of high doses of solifenacin and trospium on cognitive function and health-related quality of life in older women with urinary incontinence. Int. Neurourol. J. 22, 41\u201350 (2018).","journal-title":"Int. Neurourol. J."},{"key":"504_CR28","doi-asserted-by":"publisher","first-page":"187819","DOI":"10.1155\/2015\/187819","volume":"2015","author":"C-H Chiang","year":"2015","unstructured":"Chiang, C.-H. et al. Lower urinary tract symptoms are associated with increased risk of dementia among the elderly: a nationwide study. BioMed. Res. Int. 2015, 187819 (2015).","journal-title":"BioMed. Res. Int."},{"key":"504_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/00207458108985816","volume":"14","author":"K Syndulko","year":"2009","unstructured":"Syndulko, K. et al. Decreased verbal memory associated with anticholinergic treatment in Parkinson\u2019s disease patients. Int. J. Neurosci. 14, 61\u201366 (2009).","journal-title":"Int. J. Neurosci."},{"key":"504_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15244","author":"S Marzoughi","year":"2021","unstructured":"Marzoughi, S. et al. Tardive neurotoxicity of anticholinergic drugs: a review. J. Neurochem. https:\/\/doi.org\/10.1111\/jnc.15244 (2021).","journal-title":"J. Neurochem."},{"key":"504_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev.pharmtox.44.101802.121622","volume":"44","author":"J Wess","year":"2004","unstructured":"Wess, J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. 44, 423\u2013450 (2004).","journal-title":"Annu. Rev. Pharmacol."},{"key":"504_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","volume":"30","author":"PJ Conn","year":"2009","unstructured":"Conn, P. J., Jones, C. K. & Lindsley, C. W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 148\u2013155 (2009).","journal-title":"Trends Pharmacol. Sci."},{"key":"504_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.neuropharm.2017.11.018","volume":"136","author":"EP Lebois","year":"2018","unstructured":"Lebois, E. P., Thorn, C., Edgerton, J. R., Popiolek, M. & Xi, S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer\u2019s disease. Neuropharmacology 136, 362\u2013373 (2018).","journal-title":"Neuropharmacology"},{"key":"504_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale, J. et al. The genotype-tissue expression (GTEx) project. Nat. Genet. 45, 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"key":"504_CR35","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","volume":"11","author":"A Levey","year":"1991","unstructured":"Levey, A., Kitt, C., Simonds, W., Price, D. & Brann, M. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11, 3218\u20133226 (1991).","journal-title":"J. Neurosci."},{"key":"504_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1046\/j.1471-4159.1995.64041888.x","volume":"64","author":"DD Flynn","year":"1995","unstructured":"Flynn, D. D., Ferrari-DiLeo, G., Mash, D. C. & Levey, A. I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer\u2019s disease. J. Neurochem. 64, 1888\u20131891 (1995).","journal-title":"J. Neurochem."},{"key":"504_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/0024-3205(95)00030-A","volume":"56","author":"SM Hersch","year":"1995","unstructured":"Hersch, S. M. & Levey, A. I. Diverse pre- and post-synaptic expression of m1\u2013m4 muscarinic receptor proteins in neurons and afferents in the rat neostriatum. Life Sci. 56, 931\u2013938 (1995).","journal-title":"Life Sci."},{"key":"504_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0304-3940(90)90407-Z","volume":"116","author":"WS Messer","year":"1990","unstructured":"Messer, W. S., Bohnett, M. & Stibbe, J. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci. Lett. 116, 184\u2013189 (1990).","journal-title":"Neurosci. Lett."},{"key":"504_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras, S. G. et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 6, 51\u201358 (2003).","journal-title":"Nat. Neurosci."},{"key":"504_CR40","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","volume":"53","author":"GG Kay","year":"2005","unstructured":"Kay, G. G. et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. 53, 2195\u20132201 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.npp.1300305","volume":"29","author":"N Pomara","year":"2004","unstructured":"Pomara, N., Willoughby, L. M., Wesnes, K. & Sidtis, J. J. Increased anticholinergic challenge-induced memory impairment associated with the APOE-\u03b54 allele in the elderly: a controlled pilot study. Neuropsychopharmacology 29, 403\u2013409 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"504_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.nbd.2005.08.010","volume":"21","author":"J-F Blain","year":"2006","unstructured":"Blain, J.-F., Sullivan, P. M. & Poirier, J. A deficit in astroglial organization causes the impaired reactive sprouting in human apolipoprotein E4 targeted replacement mice. Neurobiol. Dis. 21, 505\u2013514 (2006).","journal-title":"Neurobiol. Dis."},{"key":"504_CR43","doi-asserted-by":"publisher","first-page":"e2295","DOI":"10.1212\/WNL.0000000000010643","volume":"95","author":"AJ Weigand","year":"2020","unstructured":"Weigand, A. J. et al. Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology 95, e2295\u2013e2304 (2020).","journal-title":"Neurology"},{"key":"504_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00019442-200504000-00009","volume":"13","author":"RD Jewart","year":"2005","unstructured":"Jewart, R. D., Green, J., Lu, C., Cellar, J. & Tune, L. E. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am. J. Geriatr. Psychiatry 13, 324\u2013328 (2005).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"504_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","volume":"38","author":"Y Serlin","year":"2015","unstructured":"Serlin, Y., Shelef, I., Knyazer, B. & Friedman, A. Anatomy and physiology of the blood\u2013brain barrier. Semin. Cell Dev. Biol. 38, 2\u20136 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"504_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.neubiorev.2014.11.022","volume":"49","author":"HJ van de Haar","year":"2015","unstructured":"van de Haar, H. J. et al. Blood\u2013brain barrier impairment in dementia: current and future in vivo assessments. Neurosci. Biobehav. Rev. 49, 71\u201381 (2015).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"504_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","volume":"72","author":"E Callegari","year":"2011","unstructured":"Callegari, E. et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br. J. Clin. Pharm. 72, 235\u2013246 (2011).","journal-title":"Br. J. Clin. Pharm."},{"key":"504_CR48","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4155\/tde.15.32","volume":"6","author":"WJ Geldenhuys","year":"2015","unstructured":"Geldenhuys, W. J., Mohammad, A. S., Adkins, C. E. & Lockman, P. R. Molecular determinants of blood\u2013brain barrier permeation. Ther. Deliv. 6, 961\u2013971 (2015).","journal-title":"Ther. Deliv."},{"key":"504_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/10611869808997889","volume":"6","author":"H Waterbeemd","year":"2009","unstructured":"Waterbeemd, H. van de, Camenisch, G., Folkers, G., Chretien, J. R. & Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 6, 151\u2013165 (2009).","journal-title":"J. Drug Target."},{"key":"504_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuroscience.2008.06.015","volume":"155","author":"LM Roberts","year":"2008","unstructured":"Roberts, L. M. et al. Subcellular localization of transporters along the rat blood\u2013brain barrier and blood\u2013cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience 155, 423\u2013438 (2008).","journal-title":"Neuroscience"},{"key":"504_CR51","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.027144","volume":"37","author":"J Geyer","year":"2009","unstructured":"Geyer, J., Gavrilova, O. & Petzinger, E. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab. Dispos. 37, 1371\u20131374 (2009).","journal-title":"Drug Metab. Dispos."},{"key":"504_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","volume":"29","author":"MB Chancellor","year":"2012","unstructured":"Chancellor, M. B. et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drug Aging 29, 259\u2013273 (2012).","journal-title":"Drug Aging"},{"key":"504_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1532-5415.2010.03307.x","volume":"59","author":"SM Jakobsen","year":"2011","unstructured":"Jakobsen, S. M., Kersten, H. & Molden, E. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. J. Am. Geriatr. Soc. 59, 501\u2013505 (2011).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR54","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1517\/14656566.8.4.511","volume":"8","author":"N Zinner","year":"2007","unstructured":"Zinner, N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin. Pharmacother. 8, 511\u2013523 (2007).","journal-title":"Expert Opin. Pharmacother."},{"key":"504_CR55","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1124\/jpet.108.136390","volume":"325","author":"S Maruyama","year":"2008","unstructured":"Maruyama, S. et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J. Pharmacol. Exp. Ther. 325, 774\u2013781 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"504_CR56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp.74.1.70","volume":"74","author":"JM Starr","year":"2003","unstructured":"Starr, J. M. et al. Increased blood\u2013brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 74, 70 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"504_CR57","first-page":"314","volume":"6","author":"C Pakulski","year":"2000","unstructured":"Pakulski, C., Drobnik, L. & Millo, B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 6, 314\u2013318 (2000).","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"504_CR58","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/ijcp.12164","volume":"67","author":"KS Coyne","year":"2013","unstructured":"Coyne, K. S. et al. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int. J. Clin. Pract. 67, 1015\u20131033 (2013).","journal-title":"Int. J. Clin. Pract."},{"key":"504_CR59","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1517\/14740338.2016.1165664","volume":"15","author":"PS Nishtala","year":"2016","unstructured":"Nishtala, P. S., Salahudeen, M. S. & Hilmer, S. N. Anticholinergics: theoretical and clinical overview. Expert Opin. Drug Saf. 15, 753\u2013768 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"504_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40266-019-00731-3","volume":"37","author":"MP Tan","year":"2020","unstructured":"Tan, M. P. et al. Use of medications with anticholinergic properties and the long-term risk of hospitalization for falls and fractures in the EPIC-norfolk longitudinal cohort study. Drug Aging 37, 105\u2013114 (2020).","journal-title":"Drug Aging"},{"key":"504_CR61","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s11606-020-05634-3","volume":"35","author":"N Kachru","year":"2020","unstructured":"Kachru, N., Holmes, H. M., Johnson, M. L., Chen, H. & Aparasu, R. R. Risk of mortality associated with non-selective antimuscarinic medications in older adults with dementia: a retrospective study. J. Gen. Intern. Med. 35, 2084\u20132093 (2020).","journal-title":"J. Gen. Intern. Med."},{"key":"504_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","volume":"77","author":"A Lisibach","year":"2021","unstructured":"Lisibach, A. et al. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur. J. Clin. Pharmacol. 77, 147\u2013162 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"504_CR63","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40266-018-0549-z","volume":"35","author":"TJ Welsh","year":"2018","unstructured":"Welsh, T. J., Wardt, V. van der, Ojo, G., Gordon, A. L. & Gladman, J. R. F. Anticholinergic drug burden tools\/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging 35, 523\u2013538 (2018).","journal-title":"Drugs Aging"},{"key":"504_CR64","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/gps.4844","volume":"33","author":"O Turr\u00f3-Garriga","year":"2018","unstructured":"Turr\u00f3-Garriga, O. et al. Measuring anticholinergic exposure in patients with dementia: a comparative study of nine anticholinergic risk scales. Int. J. Geriatr. Psychiatry 33, 710\u2013717 (2018).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"504_CR65","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.trci.2017.06.004","volume":"3","author":"Y-F Chuang","year":"2017","unstructured":"Chuang, Y.-F., Elango, P., Gonzalez, C. E. & Thambisetty, M. Midlife anticholinergic drug use, risk of Alzheimer\u2019s disease, and brain atrophy in community-dwelling older adults. Alzheimers Dement. 3, 471\u2013479 (2017).","journal-title":"Alzheimers Dement."},{"key":"504_CR66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher, S. L. et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 73, 721\u2013732 (2016). This study linked anticholinergic medication use to brain atrophy as measured on MRI, and worse cognitive function performance.","journal-title":"JAMA Neurol."},{"key":"504_CR67","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10639","volume":"54","author":"EK Perry","year":"2003","unstructured":"Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J. & Perry, R. H. Increased Alzheimer pathology in Parkinson\u2019s disease related to antimuscarinic drugs. Ann. Neurol. 54, 235\u2013238 (2003).","journal-title":"Ann. Neurol."},{"key":"504_CR68","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3233\/JAD-171174","volume":"65","author":"SL Gray","year":"2018","unstructured":"Gray, S. L. et al. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J. Alzheimers Dis. 65, 607\u2013616 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"504_CR69","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3233\/JAD-191199","volume":"74","author":"K Richardson","year":"2020","unstructured":"Richardson, K. et al. Neuropathological correlates of cumulative benzodiazepine and anticholinergic drug use. J. Alzheimers Dis. 74, 999\u20131009 (2020).","journal-title":"J. Alzheimers Dis."},{"key":"504_CR70","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1093\/cercor\/bhy214","volume":"29","author":"JP Chhatwal","year":"2018","unstructured":"Chhatwal, J. P. et al. Anticholinergic amnesia is mediated by alterations in human network connectivity architecture. Cereb. Cortex 29, 3445\u20133456 (2018).","journal-title":"Cereb. Cortex"},{"key":"504_CR71","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.ajog.2020.10.041","volume":"224","author":"LH Ketai","year":"2020","unstructured":"Ketai, L. H. et al. Mind-body (hypnotherapy) treatment of women with urgency urinary incontinence: changes in brain attentional networks. Am. J. Obstet. Gynecol. 224, 498.e1\u2013498.e10 (2020).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"504_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","volume":"46","author":"IR Katz","year":"1998","unstructured":"Katz, I. R. et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 46, 8\u201313 (1998).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR73","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/00912700122010528","volume":"41","author":"A Todorova","year":"2001","unstructured":"Todorova, A., Vonderheid-Guth, B. & Dimpfel, W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 41, 636\u2013644 (2001).","journal-title":"J. Clin. Pharmacol."},{"key":"504_CR74","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","volume":"56","author":"TE Lackner","year":"2008","unstructured":"Lackner, T. E., Wyman, J. F., McCarthy, T. C., Monigold, M. & Davey, C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J. Am. Geriatr. Soc. 56, 862\u2013870 (2008).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF03261924","volume":"32","author":"GG Kay","year":"2012","unstructured":"Kay, G. G., Staskin, D. R., MacDiarmid, S., McIlwain, M. & Dahl, N. V. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects. Clin. Drug Invest. 32, 707\u2013714 (2012).","journal-title":"Clin. Drug Invest."},{"key":"504_CR76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1464-410X.2005.05296.x","volume":"95","author":"K Diefenbach","year":"2005","unstructured":"Diefenbach, K. et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged \u226550 years. BJU Int. 95, 346\u2013349 (2005).","journal-title":"BJU Int."},{"key":"504_CR77","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1532-5415.2010.02988.x","volume":"58","author":"D Staskin","year":"2010","unstructured":"Staskin, D. et al. Trospium chloride is undetectable in the older human central nervous system. J. Am. Geriatr. Soc. 58, 1618\u20131619 (2010).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR78","first-page":"672","volume":"13","author":"AT Isik","year":"2009","unstructured":"Isik, A. T., Celik, T., Bozoglu, E. & Doruk, H. Trospium and cognition in patients with late onset Alzheimer disease. JNHA 13, 672 (2009).","journal-title":"JNHA"},{"key":"504_CR79","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00192-019-04140-3","volume":"31","author":"S Iyer","year":"2019","unstructured":"Iyer, S. et al. Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study. Int. Urogynecol. J. 31, 2653\u20132660 (2019).","journal-title":"Int. Urogynecol. J."},{"key":"504_CR80","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13607863.2014.922528","volume":"19","author":"E Esin","year":"2015","unstructured":"Esin, E. et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment. Health 19, 217\u2013223 (2015).","journal-title":"Aging Ment. Health"},{"key":"504_CR81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.trci.2017.01.003","volume":"3","author":"DC Moga","year":"2017","unstructured":"Moga, D. C., Abner, E. L., Wu, Q. & Jicha, G. A. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement. 3, 139\u2013148 (2017).","journal-title":"Alzheimers Dement."},{"key":"504_CR82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13195-019-0474-3","volume":"11","author":"EED Roeck","year":"2019","unstructured":"Roeck, E. E. D., Deyn, P. P. D., Dierckx, E. & Engelborghs, S. Brief cognitive screening instruments for early detection of Alzheimer\u2019s disease: a systematic review. Alzheimers Res. Ther. 11, 21 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"504_CR83","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ageing\/afaa090","volume":"49","author":"NT Pieper","year":"2020","unstructured":"Pieper, N. T. et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing 49, 939\u2013947 (2020).","journal-title":"Age Ageing"},{"key":"504_CR84","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12877-016-0251-0","volume":"16","author":"ZA Marcum","year":"2016","unstructured":"Marcum, Z. A. et al. Anticholinergic medication use and falls in postmenopausal women: findings from the Women\u2019s Health Initiative cohort study. BMC Geriatr. 16, 76 (2016).","journal-title":"BMC Geriatr."},{"key":"504_CR85","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40266-015-0257-x","volume":"32","author":"N Kachru","year":"2015","unstructured":"Kachru, N., Carnahan, R. M., Johnson, M. L. & Aparasu, R. R. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study. Drug Aging 32, 379\u2013389 (2015).","journal-title":"Drug Aging"},{"key":"504_CR86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12877-020-01657-x","volume":"20","author":"CM Grossi","year":"2020","unstructured":"Grossi, C. M. et al. Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II. BMC Geriatr. 20, 267 (2020).","journal-title":"BMC Geriatr."},{"key":"504_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hsdr08200","volume":"8","author":"CF Aldus","year":"2020","unstructured":"Aldus, C. F. et al. Undiagnosed dementia in primary care: a record linkage study. Heal. Serv. Deliv. Res. 8, 1\u2013108 (2020).","journal-title":"Heal. Serv. Deliv. Res."},{"key":"504_CR88","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray, S. L. et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern. Med. 175, 401\u2013407 (2015).","journal-title":"JAMA Intern. Med."},{"key":"504_CR89","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12877-019-1280-2","volume":"19","author":"CM Grossi","year":"2019","unstructured":"Grossi, C. M. et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatr. 19, 276 (2019).","journal-title":"BMC Geriatr."},{"key":"504_CR90","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/j.1532-5415.2011.03491.x","volume":"59","author":"C Fox","year":"2011","unstructured":"Fox, C. et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J. Am. Geriatr. Soc. 59, 1477\u20131483 (2011).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR91","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani, M., Campbell, N., Munger, S., Maidment, I. & Fox, C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Heal. 4, 311\u2013320 (2008).","journal-title":"Aging Heal."},{"key":"504_CR92","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","volume":"56","author":"ML Chew","year":"2008","unstructured":"Chew, M. L. et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 56, 1333\u20131341 (2008). An in vitro study that quantifies the actual anticholinergic effect of common medications based on clinically relevant doses, and their ability to penetrate the CNS.","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fphar.2020.00030","volume":"11","author":"Y-P Liu","year":"2020","unstructured":"Liu, Y.-P. et al. Are anticholinergic medications associated with increased risk of dementia and behavioral and psychological symptoms of dementia? A nationwide 15-year follow-up cohort study in Taiwan. Front. Pharmacol. 11, 30 (2020).","journal-title":"Front. Pharmacol."},{"key":"504_CR94","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1176\/appi.ps.201500011","volume":"66","author":"V Bali","year":"2015","unstructured":"Bali, V. et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr. Serv. 66, 1333\u20131340 (2015).","journal-title":"Psychiatr. Serv."},{"key":"504_CR95","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/jgs.15508","volume":"66","author":"L Heath","year":"2018","unstructured":"Heath, L. et al. Cumulative antidepressant use and risk of dementia in a prospective cohort study. J. Am. Geriatr. Soc. 66, 1948\u20131955 (2018).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jamda.2019.05.010","volume":"21","author":"M Hafdi","year":"2019","unstructured":"Hafdi, M. et al. Association of benzodiazepine and anticholinergic drug usage with incident dementia: a prospective cohort study of community-dwelling older adults. J. Am. Med. Dir. Assoc. 21, 188\u2013193.e3 (2019).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"504_CR97","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.parkreldis.2019.06.022","volume":"65","author":"C-T Hong","year":"2019","unstructured":"Hong, C.-T., Chan, L., Wu, D., Chen, W.-T. & Chien, L.-N. Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 65, 224\u2013229 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"504_CR98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12877-019-1401-y","volume":"19","author":"Y-C Wang","year":"2019","unstructured":"Wang, Y.-C. et al. Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatr. 19, 380 (2019).","journal-title":"BMC Geriatr."},{"key":"504_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175335","volume":"12","author":"Y-W Yang","year":"2017","unstructured":"Yang, Y.-W., Liu, H.-H., Lin, T.-H., Chuang, H.-Y. & Hsieh, T. Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS ONE 12, e0175335 (2017).","journal-title":"PLoS ONE"},{"key":"504_CR100","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/pds.5098","volume":"29","author":"D Barthold","year":"2020","unstructured":"Barthold, D., Marcum, Z. A., Gray, S. L. & Zissimopoulos, J. Alzheimer\u2019s disease and related dementias risk: comparing users of non-selective and M3-selective bladder antimuscarinic drugs. Pharmacoepidemiol. Drug Saf. 29, 1650\u20131658 (2020).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"504_CR101","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","volume":"126","author":"B Welk","year":"2020","unstructured":"Welk, B. & McArthur, E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 126, 183\u2013190 (2020). A retrospective administrative data study that demonstrated an increased risk of dementia among new users of OAB anticholinergics compared with new users of \u03b23 agonists.","journal-title":"BJU Int."},{"key":"504_CR102","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/sim.8215","volume":"38","author":"MJ Schuemie","year":"2019","unstructured":"Schuemie, M. J. et al. A plea to stop using the case-control design in retrospective database studies. Stat. Med. 38, 4199\u20134208 (2019).","journal-title":"Stat. Med."},{"key":"504_CR103","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/aje\/kwz073","volume":"188","author":"K Richardson","year":"2019","unstructured":"Richardson, K. et al. History of benzodiazepine prescriptions and risk of dementia: possible bias due to prevalent users and covariate measurement timing in a nested case-control study. Am. J. Epidemiol. 188, 1228\u20131236 (2019).","journal-title":"Am. J. Epidemiol."},{"key":"504_CR104","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jalz.2015.05.016","volume":"11","author":"M Baumgart","year":"2015","unstructured":"Baumgart, M. et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 11, 718\u2013726 (2015).","journal-title":"Alzheimers Dement."},{"key":"504_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1464-410X.2003.04271.x","volume":"92","author":"HM Dallosso","year":"2003","unstructured":"Dallosso, H. M., McGrother, C. W., Matthews, R. J. & Donaldson, M. M. K. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 92, 69\u201377 (2003).","journal-title":"BJU Int."},{"key":"504_CR106","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22362","volume":"70","author":"BL Plassman","year":"2011","unstructured":"Plassman, B. L. et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann. Neurol. 70, 418\u2013426 (2011).","journal-title":"Ann. Neurol."},{"key":"504_CR107","first-page":"49","volume":"8","author":"MS Barnish","year":"2017","unstructured":"Barnish, M. S. & Turner, S. The value of pragmatic and observational studies in health care and public health. Pragmat. Obs. Res. 8, 49\u201355 (2017).","journal-title":"Pragmat. Obs. Res."},{"key":"504_CR108","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00192-016-3258-3","volume":"28","author":"G Araklitis","year":"2017","unstructured":"Araklitis, G. et al. Anticholinergic prescription: are healthcare professionals the real burden? Int. Urogynecol. J. 28, 1249\u20131256 (2017).","journal-title":"Int. Urogynecol. J."},{"key":"504_CR109","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/nau.22928","volume":"36","author":"MA Averbeck","year":"2017","unstructured":"Averbeck, M. A., Altaweel, W., Manu-Marin, A. & Madersbacher, H. Management of LUTS in patients with dementia and associated disorders. Neurourol. Urodyn. 36, 245\u2013252 (2017).","journal-title":"Neurourol. Urodyn."},{"key":"504_CR110","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1533317519841164","volume":"34","author":"EO Caplan","year":"2019","unstructured":"Caplan, E. O. et al. Impact of coexisting overactive bladder in medicare patients with dementia on clinical and economic outcomes. Am. J. Alzheimers Dis. Other Demen. 34, 492\u2013499 (2019).","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"504_CR111","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3143\/geriatrics.36.489","volume":"36","author":"S Mori","year":"1999","unstructured":"Mori, S., Kojima, M., Sakai, Y. & Nakajima, K. Bladder dysfunction in dementia patients showing urinary incontinence. Nihon Ronen Igakkai Zasshi 36, 489\u2013494 (1999).","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"504_CR112","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"M Gannon","year":"2015","unstructured":"Gannon, M. et al. Noradrenergic dysfunction in Alzheimer\u2019s disease. Front. Neurosci. 9, 220 (2015).","journal-title":"Front. Neurosci."},{"key":"504_CR113","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling, T. L. et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 20, 109 (2020).","journal-title":"BMC Geriatr."},{"key":"504_CR114","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink, K. M. et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J. Am. Geriatr. Soc. 56, 847\u2013853 (2008).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40266-017-0510-6","volume":"35","author":"LK Triantafylidis","year":"2018","unstructured":"Triantafylidis, L. K., Clemons, J. S., Peron, E. P., Roefaro, J. & Zimmerman, K. M. Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging 35, 27\u201341 (2018).","journal-title":"Drugs Aging"},{"key":"504_CR116","unstructured":"NICE Guideline Urinary incontinence and pelvic organ prolapse in women: management (NICE, 2019)."},{"key":"504_CR117","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 10, 844\u2013852 (2014).","journal-title":"Alzheimers Dement."},{"key":"504_CR118","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jnr.490270418","volume":"27","author":"SL Dewey","year":"1990","unstructured":"Dewey, S. L. et al. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J. Neurosci. Res. 27, 569\u2013575 (1990).","journal-title":"J. Neurosci. Res."},{"key":"504_CR119","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.exger.2004.10.002","volume":"40","author":"R Norbury","year":"2005","unstructured":"Norbury, R. et al. In vivo imaging of muscarinic receptors in the aging female brain with (R,R)[123I]-I-QNB and single photon emission tomography. Exp. Gerontol. 40, 137\u2013145 (2005).","journal-title":"Exp. Gerontol."},{"key":"504_CR120","doi-asserted-by":"publisher","first-page":"100621","DOI":"10.1016\/j.conctc.2020.100621","volume":"19","author":"RA High","year":"2020","unstructured":"High, R. A. et al. Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo. Contemp. Clin. Trials Commun. 19, 100621 (2020).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"504_CR121","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/jgs.13543","volume":"63","author":"K Richardson","year":"2015","unstructured":"Richardson, K. et al. Use of medications with anticholinergic activity and self-reported injurious falls in older community-dwelling adults. J. Am. Geriatr. Soc. 63, 1561\u20131569 (2015).","journal-title":"J. Am. Geriatr. Soc."},{"key":"504_CR122","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fnagi.2019.00315","volume":"11","author":"A Rahman","year":"2019","unstructured":"Rahman, A. et al. Sex and gender driven modifiers of Alzheimer\u2019s: the role for estrogenic control across age, race, medical, and lifestyle risks. Front. Aging Neurosci. 11, 315 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"504_CR123","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/iju.12288","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara, R. et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int. J. Urol. 21, 33\u201338 (2014).","journal-title":"Int. J. Urol."},{"key":"504_CR124","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","volume":"65","author":"CC Sexton","year":"2011","unstructured":"Sexton, C. C. et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int. J. Clin. Pract. 65, 567\u2013585 (2011).","journal-title":"Int. J. Clin. Pract."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00504-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00504-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T18:04:44Z","timestamp":1675620284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-021-00504-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1038\/s41585-021-00504-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740701199.793590748","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.740701199.793590884","asserted-by":"object"}]},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"8 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}